1. Pink Sheet
  2. >>Geography

EU Backs Down In Row Over AstraZeneca Vaccine Supplies

Company Offers 9 Million Extra Doses

 
• By Andrew McConaghie

The European Commission has averted all-out conflict with AstraZeneca and the UK government, with good news from J&J and Pfizer/BioNTech easing supply concerns.

Ursula von der Leyen
The European Commission has backed away from border controls. President Ursula von der Leyen is now moving forward with plans for an EU-wide pandemic preparedness agency.

The European Union has backed down in its row with AstraZeneca and the UK over the company’s COVID-19 vaccine supplies.

This may not be the end of the matter, but the threat of legal action against AstraZeneca, and an grave escalation in post-Brexit tensions with the UK, have now receded

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Global Pharma Guidance Tracker - April 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.